Adapted first-line treatment of Helicobacter pylori infection in Algerian children

Mostefa Moubri, Nicolas Kalach, Rezki Larras, Hassina Berrah, Fouzia Mouffok, Zhor Guechi, Samy Cadranel, Mostefa Moubri, Nicolas Kalach, Rezki Larras, Hassina Berrah, Fouzia Mouffok, Zhor Guechi, Samy Cadranel

Abstract

Background: Helicobacter pylori (H. pylori) infection is acquired in early life and continues to have a high prevalence, especially in developing countries. Growing antibiotic-resistant strains necessitate adapted treatments. This study aimed to compare the efficacy, side effects, and influence of resistance of H. pylori strains between two different treatments.

Methods: This prospective, randomized blind study enrolled 112 symptomatic children infected with H. pylori (66 girls, mean age 11.1 years). Treatments, allocated randomly irrespective of the susceptibility of the strains, were either the standard omeprazole-amoxicillin-clarithromycin combination for 7 days (OAC7; group A) or omeprazole-amoxicillin with a higher dose of metronidazole (40 instead of 20 mg/kg/d) for 10 days (OAM10; group B).

Results: Before treatment, the resistance rates of H. pylori strains to metronidazole or clarithromycin were 37% and 13%, respectively, with 7% resistant to both antibiotics and neither to amoxicillin. Eradication rates obtained with OAM10 (80% by intention-to-treat [ITT] and 88% by per protocol [PP] analysis) were higher than with OAC7 (68% in ITT and 71% PP) and the differences (12% in ITT and 17% PP) were statistically significant (P=0.03). Successful treatments with OAM10 were obtained in metronidazole resistant strains and were more effective in children aged >10 years (P=0.02 by ITT and P=0.04 by PP). Only light or moderate side effects, mainly digestive, were observed.

Conclusion: Because of its therapeutic efficacy, good tolerance and lower cost the OAM10 can be considered as an appropriate first-line therapeutic scheme in Algeria.

Keywords: Helicobacter pylori; antibiotic resistance; children; first-line eradication treatment.

Conflict of interest statement

Conflict of Interest: None.

References

    1. Moosazadeh M, Lankarani KB, Afshari M. Meta-analysis of the prevalence of Helicobacter pylori infection among children and adults of Iran. Int J Prev Med. 2016;7:48.
    1. Asgeirsdottir GA, Kjartansdottir I, Olafsdottir AS, et al. Helicobacter pylori infection in Icelandic children. Scand J Gastroenterol. 2017;52:686–690.
    1. Vale FF, Vitor JM. Transmission pathway of Helicobacter pylori:does food play a role in rural and urban areas? Int J Food Microbiol. 2010;138:1–12.
    1. Daugule I, Rowland M. Helicobacter pylori infection in children. Helicobacter. 2008;13(Suppl 1):41–46.
    1. Rothenbacher D, Bode G, Adler G, Brenner H. History of antibiotic treatment and prevalence of H. pylori infection among children:results of a population-based study. J Clin Epidemiol. 1998;51:267–271.
    1. Daugule I, Rumba I, Lindkvist P, Bergström M, Ejderhamn J. A relatively low prevalence of Helicobacter pylori infection in a healthy paediatric population in Riga, Latvia:a cross-sectional study. Acta Paediatr. 2001;90:1199–1201.
    1. Malaty HM. Helicobacter pylori infection and eradication in paediatric patients. Paediatr Drugs. 2000;2:357–365.
    1. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11(Suppl 1):43–53.
    1. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut. 2006;55:1711–1716.
    1. Ahmed KS, Khan AA, Ahmed I, et al. Prevalence study to elucidate the transmission pathways of Helicobacter pylori at oral and gastroduodenal sites of a South Indian population. Singapore Med J. 2006;47:291–296.
    1. Kivi M, Tindberg Y. Helicobacter pylori occurrence and transmission:a family affair? Scand J Infect Dis. 2006;38:407–417.
    1. Czinn SJ. Helicobacter pylori infection:detection, investigation, and management. J Pediatr. 2005;146:S21–S26.
    1. Lehours P, Yilmaz O. Epidemiology of Helicobacter pylori infection. Helicobacter. 2007;12(Suppl 1):1–3.
    1. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990;161:626–633.
    1. Kalach N, Bontems P, Koletzko S, et al. Frequency and risk factors of gastric and duodenal ulcers or erosions in children:a prospective 1-month European multicenter study. Eur J Gastroenterol Hepatol. 2010;22:1174–1181.
    1. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer:evidence from a prospective investigation. BMJ. 1991;302:1302–1305.
    1. Moubri M, Larras R, Berrah H, Moufok F, Guechi Z, Touchene B. Helicobacter pylori infection in Algerian children;about 275 cases. Helicobacter. 2006;11:378.
    1. Guechi Z, Riad H, Naitkaci S. Séroprévalence de l'infection àHelicobacter pylori dans l'algérois. Journal Algérien de Médecine. 2008;16:12–14.
    1. Koletzko S, Jones NL, Goodman KJ, et al. H pylori Working Groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230–243.
    1. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents. J Pediatr Gastenterol Nutr. 2017;64:991–1003.
    1. Iwańczak BM, Borys-Iwanicka A, Biernat M, Gościniak G. Assessment of sequential and standard triple therapy in treatment of Helicobacter pylori infection in children dependent on bacteria sensitivity to antibiotics. Adv Clin Exp Med. 2016;25:701–708.
    1. Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-clarithromycin resistance in symptomatic pediatric patients in a high prevalence country. J Pediatr Gastroenterol Nutr. 2017;64:e56–e60.
    1. Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter. 2017;22
    1. Oderda G, Shcherbakov P, Bontems P, et al. European Pediatric Task Force on Helicobacter pylori. Results from the pediatric European register for treatment of Helicobacter pylori(PERTH) Helicobacter. 2007;12:150–156.
    1. Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22
    1. Khurana R, Fischbach L, Chiba N, et al. Meta-analysis Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:523–536.
    1. Moubri M, Lrras R, Berrah H, Mouffok F, Bouhadef A, Touchene B. Traitement par le régime oméprazole-amoxicilline-métronidazole de l'infection àHelicobacter pylori chez l'enfant algérien:7 jours vs 10 jours. Journal du Pédiatre Belge. 2008;10:18–20.
    1. Faber J, Bar-Meir R B, Schlesinger Y, et al. Treatment regimens for Helicobacter pylori infection in children:is in vitro susceptibility testing helpful? J Pediatr Gastroenterol Nutr. 2005;40:571–574.
    1. Nguyen TV, Bengtsson C, Nguyen GK, et al. Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children:a randomized, double-blind clinical trial. Helicobacter. 2008;13:550–556.
    1. Chen X, Ou B, Wu X, et al. Long-term therapeutic effect of triple therapy consisted of omeprazole, clarithromycin and amoxicillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment. Zhonghua Er Ke Za Zhi. 2004;42:417–420.
    1. Vilaichone RK, Ratanachu-Ek T, Gamnarai P, et al. Extremely high prevalence of metronidazole-resistant Helicobacter pylori strains in mountain people (Karen and Hmong) in Thailand. Am J Trop Med Hyg. 2016;94:717–720.
    1. Schwarzer A, Urruzuno P, Iwańczak B, et al. ESPGHAN Working Group on Helicobacter pylori Infection. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr. 2011;52:424–428.
    1. Miendje Deyi VY, Deyi VY, Bontems P, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011;49:2200–2209.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.
    1. Kalach N, Serhal L, Asmar E, et al. Helicobacter pylori primary resistant strains over 11 years in French children. Diag Microbiol Infect Dis. 2007;59:217–222.
    1. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol. 2002;35:315–320.
    1. Bardhan K, Bayerdörffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER Study:the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter. 2000;5:196–201.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe